<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173964</url>
  </required_header>
  <id_info>
    <org_study_id>Pin-2014-SNUBH</org_study_id>
    <nct_id>NCT02173964</nct_id>
  </id_info>
  <brief_title>Pinverin Application Trial to Reduce Bowel Uptake of FDG (Fluorodeoxyglucose)</brief_title>
  <official_title>Clinical Trial of Pinverin (Pinaverium Bromide) to Reduce Bowel Uptake of FDG in a Variety of Cancer Patients Who Undergo FDG PET/CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Background

             1. PET/CT (positron emission tomography/computed tomography) using FDG
                (fluorodeoxyglucose) is widely used for evaluation of cancer patients.

             2. Bowel uptake of FDG is a serious problem that hampers the proper reading of PET/CT.

             3. There is no widely-accepted method to reduce the bowel FDG uptake.

        2. Purpose

             1. To know whether pinverin (pinaverium bromide) application during PET/CT can reduce
                bowel uptake of FDG.

             2. Pinverin is a calcium-channel blocker that ameliorates the bowel contraction.

             3. Pinverin may be useful to reduce bowel FDG uptake by ameliorating the bowel
                contraction during PET/CT acquisition.

        3. Method

             1. Intervention versus control: administration of single tablet of pinverin (50mg)
                perorally versus simple water (~100mL).

             2. Timing of administration: At the time of FDG injection. PET/CT images will be
                acquired 1hr post FDG injection.

        4. Primary outcome

             1. SUV (standardized uptake value) difference between pinverin administered patient
                group versus control group.

             2. SUV (standardized uptake value) is calculated as: (decay corrected radioactivity in
                mCi/mL) x (body weight in g) / (injected radioactivity in mCi)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SUV (standardized uptake value)</measure>
    <time_frame>1 hour after FDG (the radiopharmaceutical for PET/CT) injection</time_frame>
    <description>SUV is the quantitative parameter of FDG uptake during PET/CT and represents the degree of relative FDG uptake in a specific lesion.
SUV is calculated as: (decay-corrected radioactivity in mCi/mL) x (body weight in g) / (injected radioactivity in mCi). The unit of SUV is g/mL.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>pinaverium bromide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pinaverium bromide 50 mg tablet per oral administration one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>water ~100mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pinaverium bromide</intervention_name>
    <description>pinverin 50 mg per oral single dose versus simple water ingestion</description>
    <arm_group_label>pinaverium bromide</arm_group_label>
    <other_name>pinverin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>water</intervention_name>
    <description>same amount of water for pinverin administration</description>
    <arm_group_label>water</arm_group_label>
    <other_name>water~100mL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any cancer patients

          -  Candidate of positron emission tomography/computed tomography

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Inflammatory bowel disease

          -  Irritable bowel syndrome

          -  Peritoneal carcinomatosis

          -  Peritonitis

          -  Abdominal pain

          -  Diarrhea

          -  Medical test requiring bowel preparation within 1 month

          -  History of abdominal surgery

          -  Symptom or sign of colitis

          -  Pregnancy or lactation

          -  Hypersensitivity to pinaverium bromide

          -  Lactate intolerance

          -  Anit-depressant medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Woo Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <last_update_submitted>April 13, 2016</last_update_submitted>
  <last_update_submitted_qc>April 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Won Woo Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>fluorodeoxyglucose</keyword>
  <keyword>positron emission tomography</keyword>
  <keyword>computed tomography</keyword>
  <keyword>bowel</keyword>
  <keyword>pinaverium bromide</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
    <mesh_term>Pinaverium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

